OrganOx® limited is a medical device company with a mission to increase the quality and supply of organs for transplantation.
OrganOx’s first product, the OrganOx metra® enables the repair, preservation and viability assessment of livers prior to transplantation, for up to 24 hours using normothermic oxygenated blood.
The OrganOx technology is designed to create a body-mimicking environment around the liver, providing oxygen and nutrition at physiological flow rates and pressures, using the patented process of “auto-regulation”.
OrganOx has recently completed a controlled clinical study in the UK, with results due to be announced soon. Further clinical studies are underway in Europe and planned in the US, with European product launch of a CE marked device expected in 2015.